Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
A Webb, David Cunningham, J. Howard Scarffe et al. · Journal of Clinical Oncology · 1997
PURPOSE: We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous infusion fluorouracil (5-FU) (ECF regimen) with the standard combination of 5-FU, doxorubicin, and methotrexate (FAMTX) in previously untreated patients with advanced esophagogastric cancer. PATIENTS AND METHODS: Two hundred seventy-four patients with adenocarcinoma or undifferentiated carcinoma were randomized and analyzed for survival, tumor response, toxicity, and quality of life (QL). RESULTS: The overall response rate was 45% (95% confidence interval [CI], 36% to 54%) with ECF and 21% (95% CI, 13% to 29%) with FAMTX (P = .0002). Toxicity was tolerable and there were only three toxic deaths. The FAMTX regimen caused more hematologic toxicity and serious infections, but ECF caused more emesis and alopecia. The median survival duration was 8.9 months with ECF and 5.7 months with FAMTX (P = .0009); at 1 year, 36% (95% CI, 27% to 45%) of ECF and 21% (95% CI, 14% to 29%) of FAMTX patients were alive. The median failure-free survival duration was 7.4 months with ECF and 3.4 months with FAMTX (P = .00006). The global QL scores were better for ECF at 24 weeks, but the remaining QL data showed no differences between either arm of the study. Hospital-based cost analysis on a subset of patients was similar for each arm and translated into an increment cost of $975 per life-year gained. CONCLUSION: The ECF regimen results in a survival and response advantage, tolerable toxicity, better QL and cost-effectiveness compared with FAMTX chemotherapy. This regimen should now be considered the standard treatment for advanced esophagogastric cancer.
Cited by 870 works. doi:10.1200/jco.1997.15.1.261
Authors
- David Cunningham
- J. Howard Scarffe
- Peter Harper
- Andrew Richard Norman
- Johnathan Joffe
- Janine Mansi
- M Findlay
- J. R. Oates
- Marianne C. Nicolson
- Tamas Hickish
- Mary E.R. O'Brien
- Timothy J. Iveson
- Maggie Watson
- Craig R. Underhill
- Andrew M. Wardley
- M Meehan
References
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Health-related quality of life measurement for evaluation research and policy analysis.
- A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
- Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters
- Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer
- Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.
- Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer.
- Long-term Cost-effectiveness of Various Initial Monotherapies for Mild to Moderate Hypertension
- Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses